Changes after publication

Changes after publication

February 2014: implementation section updated to clarify that rituximab is recommended as an option for treating chronic lymphocytic leukaemia. Additional minor maintenance update also carried out.

March 2012: minor maintenance

  • National Institute for Health and Care Excellence (NICE)